NCT00755170 - Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Vinorelbine

Metronomic vinorelbine (p.o) 30 mg total dose/day, every Monday, Wednesday and Friday of each week, continuously without intervals for the equivalence of 6 cycles maximum

DRUG

Bevacizumab

Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression

Trial Locations (9)

Unknown

University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupoli

"IASO General Hospital of Athens, 1st Dep of Medical Oncology", Athens

"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens

401 Military Hospital of Athens, Athens

Air Forces Military Hospital of Athens, Athens

University Hospital of Crete, Dep of Medical Oncology, Heraklion

State General Hospital of Larissa, Dep of Medical Oncology, Larissa

"Theagenion Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology", Thessaloniki

Interbalkan Hospital, division of Oncology, Pylaia, Thessaloniki, Thessaloniki